Faculties of Pharmacy, Université de Montréal, Montréal, Que.
CMAJ. 2010 Mar 23;182(5):447-55. doi: 10.1503/cmaj.090533. Epub 2010 Mar 8.
Few studies have reported the efficacy of collaborative care involving family physicians and community pharmacists for patients with dyslipidemia.
We randomly assigned clusters consisting of at least two physicians and at least four pharmacists to provide collaborative care or usual care. Under the collaborative care model, pharmacists counselled patients about their medications, requested laboratory tests, monitored the effectiveness and safety of medications and patients' adherence to therapy, and adjusted medication dosages. After 12 months of follow-up, we assessed changes in low-density lipoprotein (LDL) cholesterol (the primary outcome), the proportion of patients reaching their target lipid levels and changes in other risk factors.
Fifteen clusters representing a total of 77 physicians and 108 pharmacists were initially recruited, and a total of 51 physicians and 49 pharmacists were included in the final analyses. The collaborative care teams followed a total of 108 patients, and the usual care teams followed a total of 117 patients. At baseline, mean LDL cholesterol level was higher in the collaborative care group (3.5 v. 3.2 mmol/L, p = 0.05). During the study, patients in the collaborative care group were less likely to receive high-potency statins (11% v. 40%), had more visits with health care professionals and more laboratory tests, were more likely to have their lipid-lowering treatment changed and were more likely to report lifestyle changes. At 12 months, the crude incremental mean reduction in LDL cholesterol in the collaborative care group was -0.2 mmol/L (95% confidence interval [CI] -0.3 to -0.1), and the adjusted reduction was -0.05 (95% CI -0.3 to 0.2). The crude relative risk of achieving lipid targets for patients in the collaborative care group was 1.10 (95% CI 0.95 to 1.26), and the adjusted relative risk was 1.16 (95% CI 1.01 to 1.34).
Collaborative care involving physicians and pharmacists had no significant clinical impact on lipid control in patients with dyslipidemia. International Standard Randomized Controlled Trial register no. ISRCTN66345533.
很少有研究报告涉及家庭医生和社区药剂师共同参与的协同护理对血脂异常患者的疗效。
我们将至少由两名医生和至少四名药剂师组成的群组随机分配至协同护理组或常规护理组。在协同护理模式下,药剂师为患者提供药物咨询、检验申请、监测药物效果和安全性以及患者治疗依从性,并调整药物剂量。经过 12 个月的随访,我们评估了低密度脂蛋白(LDL)胆固醇的变化(主要结局)、达到目标血脂水平的患者比例以及其他危险因素的变化。
最初招募了 15 个代表共 77 名医生和 108 名药剂师的群组,最终有 51 名医生和 49 名药剂师纳入最终分析。协同护理团队共随访了 108 名患者,常规护理团队共随访了 117 名患者。在基线时,协同护理组的平均 LDL 胆固醇水平较高(3.5 v. 3.2 mmol/L,p = 0.05)。在研究期间,协同护理组的患者较少接受高强度他汀类药物治疗(11% v. 40%),接受更多的医疗保健专业人员就诊和更多的实验室检查,更有可能改变降脂治疗,更有可能报告生活方式的改变。在 12 个月时,协同护理组 LDL 胆固醇的未校正平均增量降低为-0.2 mmol/L(95%置信区间 [CI] -0.3 至 -0.1),校正后降低为-0.05(95% CI -0.3 至 0.2)。协同护理组患者达到血脂目标的粗相对风险为 1.10(95% CI 0.95 至 1.26),校正后的相对风险为 1.16(95% CI 1.01 至 1.34)。
涉及医生和药剂师的协同护理对血脂异常患者的血脂控制没有显著的临床影响。国际标准随机对照试验注册号 ISRCTN66345533。